Cancer Therapy-Related Cardiac Dysfunction: Strategies for Enhancing Cardiac Recovery.
Methodist Debakey Cardiovasc J
; 20(4): 109-112, 2024.
Article
em En
| MEDLINE
| ID: mdl-39184162
ABSTRACT
Chemotherapy has markedly improved cancer outcomes, yet cancer therapy-related cardiac dysfunction (CTRCD) poses a significant challenge, affecting around 10% of patients. CTRCD can be asymptomatic or present with heart failure symptoms. Multimodality imaging, particularly echocardiography, remains pivotal for monitoring cardiac function. Potential biomarkers for CTRCD assessment include troponin and B-type natriuretic peptide. Pharmacological interventions, such as dexrazoxane, angiotensin-converting enzyme inhibitors, and statins, play a crucial role in primary prevention and mitigating cardiotoxicity alongside cardiac rehabilitation programs. Thus, a comprehensive approach is essential for optimal cardiac recovery and improved patient outcomes.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Recuperação de Função Fisiológica
/
Cardiotoxicidade
/
Cardiopatias
/
Neoplasias
/
Antineoplásicos
Limite:
Humans
Idioma:
En
Revista:
Methodist Debakey Cardiovasc J
Assunto da revista:
ANGIOLOGIA
/
CARDIOLOGIA
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
México
País de publicação:
Estados Unidos